Bristol-Myers Squibb Co [BMY] stock prices are down -3.90% to $56.22 at the moment. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The BMY shares have gain 3.84% over the last week, with a monthly amount glided 5.72%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Previously, Daiwa Securities upgraded its rating to Outperform on November 13, 2024. On November 12, 2024, upgrade upgraded it’s rating to Outperform but maintained its price target of $73 on the stock. Citigroup downgraded its rating to a Neutral and decreased its price target to $55 on October 25, 2024. Bernstein initiated its recommendation with a Mkt Perform and recommended $56 as its price target on October 17, 2024. Barclays downgraded its rating to Equal Weight for this stock on July 29, 2024, but kept the price target unchanged to $41. In a note dated March 11, 2024, Societe Generale downgraded an Hold rating on this stock.
The stock price of Bristol-Myers Squibb Co [BMY] has been fluctuating between $39.35 and $61.08 over the past year. Currently, Wall Street analysts expect the stock to reach $65.5 within the next 12 months. Bristol-Myers Squibb Co [NYSE: BMY] shares were valued at $56.22 at the most recent close of the market. An investor can expect a potential return of 16.51% based on the average BMY price forecast.
Analyzing the BMY fundamentals
The Bristol-Myers Squibb Co [NYSE:BMY] reported sales of 47.44B for trailing twelve months, representing a surge of 8.44%. Gross Profit Margin for this corporation currently stands at 0.7% with Operating Profit Margin at 0.27%, Pretax Profit Margin comes in at -0.15%, and Net Profit Margin reading is -0.15%. To continue investigating profitability, this company’s Return on Assets is posted at -0.08, Equity is -0.36 and Total Capital is 0.18. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of2.9.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 55.24 points at the first support level, and at 54.26 for the second support level. However, for the 1st resistance point, the stock is sitting at 57.78, and for the 2nd resistance point, it is at 59.34.
Ratios To Look Out For
It’s worth pointing out that Bristol-Myers Squibb Co [NYSE:BMY]’s Current Ratio is 1.24. As well, the Quick Ratio is 1.09, while the Cash Ratio is 0.35. Considering the valuation of this stock, the price to sales ratio is 2.31, the price to book ratio is 6.65.
Transactions by insiders
Recent insider trading involved Holzer Phil M, SVP and Controller, that happened on Nov 04 ’24 when 700.0 shares were sold. EVP,Chief Med.Offr.,Drug Dev., Hirawat Samit completed a deal on Nov 01 ’24 to buy 1830.0 shares. Meanwhile, Officer Holzer Phil M bought 700.0 shares on Nov 04 ’24.
